araag2/HINT huggingface dataset:
Clinical trial NCT02797132 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: lum/iva
SMILES: CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who weigh ≥8 kilogram (kg) without shoes and wearing light clothing at the
             Screening Visit

          -  Subjects with confirmed diagnosis of CF at the Screening Visit

          -  Subjects who are homozygous for the F508del-cystic fibrosis transmembrane conductance
             regulator (CFTR) mutation

        Exclusion Criteria:

          -  Any clinically significant laboratory abnormalities at the Screening Visit that would
             interfere with the study assessments or pose an undue risk for the subject

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 28 days before Day 1

          -  A standard 12-lead ECG demonstrating QTc >450 millisecond (msec) at the Screening
             Visit.

          -  History of solid organ or hematological transplantation.

          -  Ongoing or prior participation in an investigational drug study (including studies
             investigating LUM and/or IVA) within 30 days of the Screening Visit.

          -  History of cataract/lens opacity or evidence of cataract/lens opacity determined to be
             clinically significant by a licensed ophthalmologist during the ophthalmologic
             examination at the Screening Visit
Clinical trial NCT02801617 (phase 3, status: terminated)
Conditions: primary open angle glaucoma, ocular hypertension
ICD codes: H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, H40.1111, H40.053, H40.051, H40.052, H40.059
Drugs: pro-067, gaap ofteno®
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Reason stopped: 
    expiration time limit of recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Female or male

          -  Age: ≥18 years old

          -  Patients with primary open angle glaucoma with mild to moderate damage or ocular
             hypertension that were sufficiently controlled with GAAP Ofteno® (latanoprost 0.005%)
             within the last 60 days

          -  Signed Informed Consent Form

        Exclusion Criteria:

          -  Subjects with unique eye

          -  Subjects with visual acuity < 20/200

          -  Another kind of glaucoma disease different to primary open angle glaucoma

          -  corneal disturbances with impossibility to measure the intraocular pressure

          -  retinal alterations without control or progressive retinal disease with high risk to
             lost vision
Clinical trial NCT02806141 (phase 3, status: terminated)
Conditions: pneumonia, ventilator-associated, colistin adverse reaction, infection due to multidrug resistant acinetobacter, infection resistant to multiple drugs
ICD codes: J95.851
Drugs: aerosolized plus intravenous colistin, intravenous colistin
SMILES: CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O, CCC(C)CCCCC(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS([O-])(=O)=O)NC1=O)C(C)O
Reason stopped: 
    no patient included at target sample sizes
  
Eligibility criteria:

        Inclusion Criteria:

          -  Neonates who are admitted to the neonatal intensive care unit, Hat Yai Hospital during
             the study period.

          -  Neonates who were complicated with VAP due to PDR-Acinetobacter baumannii susceptible
             to colistin (by minimal inhibitory concentration (MIC) < 2 mcg/dL).

        Exclusion Criteria:

          -  Neonates who have a major anomaly or chromosomal abnormality.

          -  Neonates who receive colistin prior 7 days prior to study.

          -  Neonates who have a significant renal dysfunction defined as a serum creatinine (SCr)
             >1.5 mg/dL or a decrease in urine output to < 1 mL/kg/h;
Clinical trial NCT02807064 (phase 3, status: unknown status)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: bifidobacteria, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Children of both sexes , aged from 4 to 17 years

          -  History seasonal allergic rhinitis mild , moderate or severe , according to the
             guidelines defined AIR 2013 , documented by recurrent episodes in the previous year
             and confirmed by skin prick test positive

          -  Written informed consent of one parent or a legal representative

        Exclusion Criteria:

          -  Lack of written informed consent by at least one parent or a legal representative

          -  Concurrent disorders such as infection of the upper or lower respiratory tract , nasal
             surgery in the past year , respiratory tract abnormalities , immune diseases

          -  Use of antihistamines , nasal or systemic corticosteroids , leukotriene modifiers , or
             cromolyn sodium , on an ongoing basis used in the last six weeks.
Clinical trial NCT02813265 (phase 3, status: completed)
Conditions: dry eye syndromes, keratoconjunctivitis sicca
ICD codes: H04.121, H04.122, H04.123, H04.129, H16.223, H16.221, H16.222, H16.229
Drugs: kpi-121 0.25% ophthalmic suspension, vehicle of kpi-121 0.25% ophthalmic suspension
SMILES: [H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Have a documented clinical diagnosis of dry eye disease in both eyes

        Exclusion Criteria:

          -  Known hypersensitivity or contraindication to the investigational product(s) or
             components

          -  History of glaucoma, Intraocular Pressure (IOP) >21 mmHg at the screening or
             randomization visits, or being treated for glaucoma in either eye.

          -  Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in
             judgment of Investigator could confound study assessments or limit compliance; or have
             been exposed to an investigational drug within 30 days prior to screening.

          -  In the opinion of the Investigator or study coordinator, be unwilling or unable to
             comply with study protocol or unable to successfully instill eye drops.
Clinical trial NCT02814643 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: benralizumab, benralizumab placebo, seasonal influenza virus vaccine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female and male patients aged 12 to 21 years, inclusive, at the time of Visit 1

          -  Weight of ≥40 kg

          -  Documented history of current treatment with Inhaled corticosteroids (ICS) and
             long-acting β2 agonists (LABA)

          -  Morning pre-bronchodilator forced expiratory volume in 1 second (FEV1) of >50%
             predicted at Visit 1 or Visit 2.

          -  Airway reversibility (FEV1 >12% and 200 ml) demonstrated at Visit 1 or Visit 2 using
             the Maximum Post-bronchodilator Procedure OR

          -  Airway reversibility documented in the previous 12 months prior to Visit 1

          -  An exacerbation, 1 or more, that required oral corticosteroids in the previous year OR

          -  Any condition assessed by patient recall over the previous 2-4 weeks

        Exclusion Criteria:

          -  Clinically important pulmonary disease other than asthma

          -  Known history of allergy or reaction to the Investigational Product formulation or
             influenza vaccine

          -  Receipt of an influenza vaccine within 90 days prior to randomization

          -  Poorly controlled asthma during the screening period that requires treatment with oral
             corticosteroids or a hospitalization/emergency room visit for the treatment of asthma

          -  Acute illness or evidence of significant active infection or known influenza infection
             during the current flu season
Clinical trial NCT02815709 (phase 3, status: completed)
Conditions: acute pain
ICD codes: G89.12, G89.18, G89.11, G89.3
Drugs: oliceridine, placebo, morphine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Has undergone primary, unilateral, first metatarsal bunionectomy (osteotomy and
             internal fixation) with no additional collateral procedures.

          -  Experiences a pain intensity rating of moderate to severe acute pain.

          -  Able to provide written informed consent before any study procedure.

        Exclusion Criteria:

          -  ASA Physical Status Classification System classification of P3 or worse.

          -  Has surgical or post-surgical complications.

          -  Has clinically significant medical conditions or history of such conditions that may
             interfere with the interpretation of efficacy, safety, or tolerability data obtained
             in the trial, or may interfere with the absorption, distribution, metabolism, or
             excretion of drugs.

          -  Has previously participated in another TRV130 clinical study.
Clinical trial NCT02819284 (phase 3, status: completed)
Conditions: dry eye syndromes, keratoconjunctivitis sicca
ICD codes: H04.121, H04.122, H04.123, H04.129, H16.223, H16.221, H16.222, H16.229
Drugs: kpi-121 0.25% ophthalmic suspension, vehicle of kpi-121 0.25% ophthalmic suspension
SMILES: [H][C@@]12CC[C@](O)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Have a documented clinical diagnosis of dry eye disease in both eyes

        Exclusion Criteria:

          -  Known hypersensitivity or contraindication to the investigational product(s) or
             components

          -  History of glaucoma, IOP>21 mmHg at the screening or randomization visits, or being
             treated for glaucoma in either eye.

          -  Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in
             judgment of Investigator could confound study assessments or limit compliance; or have
             been exposed to an investigational drug within 30 days prior to screening.

          -  In the opinion of the Investigator or study coordinator, be unwilling or unable to
             comply with study protocol or unable to successfully instill eye drops.
Clinical trial NCT02820324 (phase 3, status: completed)
Conditions: acute pain
ICD codes: G89.12, G89.18, G89.11, G89.3
Drugs: oliceridine, placebo, morphine
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Has undergone abdominoplasty with no additional collateral procedures.

          -  Experiences a pain intensity rating of moderate to severe acute pain.

          -  Able to provide written informed consent before any study procedure.

        Exclusion Criteria:

          -  ASA Physical Status Classification System classification of P3 or worse.

          -  Has surgical or post-surgical complications.

          -  Has clinically significant medical conditions or history of such conditions that may
             interfere with the interpretation of efficacy, safety, or tolerability data obtained
             in the trial, or may interfere with the absorption, distribution, metabolism, or
             excretion of drugs.

          -  Has previously participated in another TRV130 clinical study.
Clinical trial NCT02822742 (phase 3, status: completed)
Conditions: primary open angle glaucoma or ocular hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: de-117 ophthalmic solution, latanoprost ophthalmic solution 0.005%
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Primary open angle glaucoma or ocular hypertension

        Exclusion Criteria:

          -  Patients at risk of progression of visual field loss

          -  Patients with severe visual field defect

          -  Patients with any diseases that preclude participation in this study for safety
             reasons
Clinical trial NCT02825251 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: faster-acting insulin aspart, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age at least 18 years at the time of signing the informed consent

          -  Diagnosed with T1DM (Type 1 Diabetes Mellitus) (based on clinical judgement and/or
             supported by laboratory analysis as per local guidelines) equal or above 1 year prior
             to the day of screening

          -  Using the same Medtronic pump (Minimed 530G (551/751), Paradigm Veo (554/754),
             Paradigm Revel (523/723), Paradigm (522/722)) for CSII in a basal-bolus regimen with a
             rapid acting insulin analogue for at least six months prior to screening and willing
             to stay on the same pump model throughout the trial (if the model is changed the
             change should not exceed 7 consecutive days.)

          -  HbA1c (glycosylated haemoglobin) 7.0-9.0% (53-75 mmol/mol) as assessed by central
             laboratory at screening

          -  Body mass index (BMI) below or equal to 35.0 kg/m^2 at screening

          -  Ability and willingness to take at least 3 daily meal-time insulin bolus infusions
             every day throughout the trial

        Exclusion Criteria:

          -  Any of the following: myocardial infarction, stroke, hospitalization for unstable
             angina or transient ischaemic attack within the past 180 days prior to the day of
             screening

          -  Planned coronary, carotid or peripheral artery revascularisation known on the day of
             screening

          -  History of hospitalization for ketoacidosis below or equal to 180 days prior to the
             day of screening

          -  Treatment with any medication for the indication of diabetes or obesity other than
             stated in the inclusion criteria in a period of 90 days before screening

          -  Any condition which, in the opinion of the Investigator, might jeopardise a Subject's
             safety or compliance with the protocol
Clinical trial NCT02832570 (phase 3, status: completed)
Conditions: peripheral arterial occlusive disease
ICD codes: A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, I73.9
Drugs: sildenafil 100mg single oral dose, placebo, oral intake single dose
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with peripheral arterial desease stade II

          -  Patient with vascular claudication for at least 3 months

          -  Patient able to perform a treadmill walking test with time to walk < 5min

        Exclusion Criteria:

          -  Patient suffering from ischemia

          -  Previous angina or myocardial

          -  Patient treated with nitrates drugs

          -  Patient with severe renal insufficiency

          -  Patient with severe hepatic insufficiency

          -  Patient with hypotension
Clinical trial NCT02836873 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: bexagliflozin, placebo
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(Cl)C(CC2=CC=C(OCCOC3CC3)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males or females with T2DM with inadequate glycemic control

          2. Diagnosis of moderate renal impairment

        4) Body Mass Index ≤ 45 kg/m2

        Exclusion Criteria:

          1. Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young

          2. Women who are pregnant or nursing

          3. Subjects who are receiving renal replacement therapy or have undergone renal
             transplantation
Clinical trial NCT02842086 (phase 3, status: active, not recruiting)
Conditions: pre-exposure prophylaxis of hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: f/taf, f/tdf, f/taf placebo, f/tdf placebo
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Must be at high risk of sexual acquisition of HIV

          -  HIV-1 negative status

          -  MSM and TGW (male at birth) who have at least one of the following:

               -  condomless anal intercourse with at least two unique male partners in the past 12
                  weeks (partners must be either HIV-infected or of unknown HIV status)

               -  documented history of syphilis in the past 24 weeks

               -  documented history of rectal gonorrhea or chlamydia in the past 24 weeks

          -  Adequate renal function: estimated glomerular filtration rate ≥ 60 mL/min according to
             the Cockcroft-Gault formula

          -  Adequate liver and hematologic function:

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper
                  limit of normal (ULN) and total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin

               -  Absolute neutrophil count ≥ 1000/mm^3; platelets ≥ 75,000/mm^3; hemoglobin ≥ 10
                  g/dL

        Key Exclusion Criteria

          -  Grade 3 or Grade 4 proteinuria or glycosuria that is unexplained or not clinically
             manageable.

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT02849951 (phase 3, status: terminated)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: lt-02, lt-02 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lt-02 did not appear to help induce remission of uc
  
Eligibility criteria:

        Key Inclusion Criteria:

          1. Established diagnosis of ulcerative colitis (UC), based on clinical history, exclusion
             of infectious causes, and characteristic endoscopic and histologic findings.

          2. Active UC with disease confirmed by endoscopy findings and confirmed by central
             reader.

          3. A modified Mayo Score 4-10, and with a centrally read endoscopy score activity of ≥ 2
             points.

          4. Mesalamine (5-ASA) refractory.

        Exclusion Criteria:

          1. Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, radiation
             colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis),
             diverticular disease associated colitis,

          2. Toxic megacolon or fulminant colitis,

          3. Prior colon resection,

          4. Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile
             infection) at screening,

          5. Known celiac disease

          6. Other inflammatory or bleeding disorders of the colon and intestine, or diseases what
             may cause diarrhea or gastrointestinal bleeding

          7. History or presence of ischemic heart disease, myocardial infarction, peripheral
             arterial disease, ischemic stroke, or transient ischemic attack,

          8. Subjects with known hypersensitivity to soy,

          9. Treatment with methotrexate, azathioprine, 6-mercaptopurine TNF-alpha-antagonists,
             vedolizumab or certolizumab pegol, tacrolimus, or anti-integrin therapy within last 8
             weeks prior to screening,

         10. Treatment with any (topical or systemic) corticosteroid formulation for the treatment
             of IBD within last 7 days prior to endoscopy,

         11. Treatment with other investigational drug within last 8 weeks prior to screening,
Clinical trial NCT02858453 (phase 3, status: unknown status)
Conditions: interstitial cystitis, bladder pain syndrome, painful bladder syndrome, chronic interstitial cystitis
ICD codes: N30.10, N30.11, R39.82, D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: aqx-1125 100 mg, aqx-1125 200 mg, placebo
SMILES: C[C@]12CC[C@@H]([C@@H](CN)[C@@H]1CCC2=C)[C@@]1(C)CC[C@H](O)C[C@@H]1CO, C[C@]12CC[C@@H]([C@@H](CN)[C@@H]1CCC2=C)[C@@]1(C)CC[C@H](O)C[C@@H]1CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Be male or female, ≥18 and ≤80 years of age who have had symptoms of bladder pain in
             addition to urinary urgency and/or urinary frequency for more than 6 months

          -  Have had a clinical diagnosis, or history consistent with the diagnosis, of
             interstitial cystitis/bladder pain syndrome for >3 months but ≤20 years

          -  Must be capable of voiding independently

          -  Have undergone a cystoscopy within the last 36 months prior to Baseline

          -  Women of child bearing potential must have a negative pregnancy test, be non-lactating
             and agree to avoid pregnancy and use a highly effective method of contraception with
             one additional barrier method of contraception from screening until at least 28 days
             after the last dose of study drug has been taken

          -  Men must use a condom for sexual intercourse from screening until at least 90 days
             after last dose of study drug has been taken, unless they have been surgically
             sterilized (vasectomy)

        Exclusion Criteria

          -  Have had a urinary tract infection (UTI) including bacterial cystitis within the past
             30 days

          -  Microscopic hematuria that has not been adequately evaluated as per local standard of
             care

          -  Have a history of chronic substance abuse, dependency or abuse of opiates, or other
             narcotics within the last 2 years

          -  History of previous procedure(s) (augmentation cystoplasty, cystectomy, cytolysis,
             botulinum toxin or bladder catheterization) that has significantly affected bladder
             function

          -  History of cyclophosphamide or chemical cystitis, urinary tuberculosis or radiation
             cystitis

          -  Women: History of bladder tumors; uterine, cervical, vaginal or urethral cancer

          -  Men: History of prostate surgery (transurethral resection of the prostate [TURP],
             transurethral resection tumor [TURT], transurethral incision of the prostate [TUIP],
             transurethral needle ablation [TUNA] etc.), a history of prostate cancer or currently
             being treated for chronic bacterial prostatitis

          -  Major surgery within 3 months prior to Screening